SEER

1.3601.81%
NH

Nicolas Henry Roelofs

Lead Independent Director

Dr. Nicolas Henry Roelofs, also known as Nick, Ph.D., serves as Lead Independent Director of Seer, Inc. since August 13, 2024. He serves as Venture Partner at Sciety AB since 2024. He has been an Independent Director at DA32 Life Science Tech Acquisition Corp. since July 27, 2021. Dr. Roelofs has been an Advising Partner for Summa Equity since 2019 and an Industrial Advisor with Nordic Capital LTD since 2014. He has been the Chairman and Independent Director at Bluebee Holding B.V. since May 08, 2017 and a Non-Executive Director at LGC Limited since joining the Board in April 2016. Dr. Roelofs also serves as Director and Board Member of One Biomed Pte. Ltd., Director of Capitainer AB, Chairman of Sengenics Corporation LLC, a board member of Velsera, a board member of LGC Group, an advisory board member of 908 Devices Inc., Chairman and Director at Boreal Genomics Inc., and holds a board position at PeptiSystems. He served as the Advisor of Summa Equity AB from February 2024. He served as a Director at Axion BioSystems, Inc. from January 2022 to January 2023. Dr. Roelofs had been a Director at Olink Holding AB (publ) since 2018. He served as a Director of Biolidics Limited, also known as Clearbridge Biomedics Pte Ltd, until September 19, 2018. He also served as a Director of Clear Labs, Inc., a Director of ScaleBio Ltd., and held a board appointment at The Binding Site. From 2010 to 2013, he served on the Advisory Board of Chemical & Engineering News for the American Chemical Society Magazine. He served as Senior Vice President and President of the Life Sciences Group at Agilent Technologies, Inc. from September 2009 to September 2013 and also served as Vice President and General Manager of Life Sciences Solutions Unit for Life Sciences and Chemical Analysis group of the company from June 2006 to September 2009. From 2004 to 2005, he was with Bio-Rad Laboratories, Inc., where he served as Group Operations Officer of the protein separations and analysis, genomics and food science business. He served as the Chief Operating Officer of Stratagene Corporation from August 2003 to December 31, 2004 and also served as its Senior Vice President of Marketing & Asian Sales from 2001 to 2005. Prior to 2001, he served as Business Unit Director of Applied Biosystems, where he was employed from 1997 to 2001. He was at Baxter Healthcare from 1989 to 1997. Dr. Roelofs has several years of international leadership experience in the Life Sciences and Diagnostics industry and has been directly involved in several start-up companies. He has been involved in numerous acquisitions, divestments and exits through executive, advisory and board roles. His contributions during his term at Agilent Technologies, Inc., in the areas of business development, sales, manufacturing, R&D and marketing saw him play a key role in the life science business. Dr. Roelofs has contributed to innovation in molecular diagnostics and played a role in the development and/or commercialisation of numerous PCR technologies or products. He has also been directly involved in technologies around nucleic acid synthesis, single cell detection, antibody production and Next Generation Sequencing. At Sciety, he draws on his scientific, commercial and investment expertise to evaluate investment opportunities and support portfolio companies in their growth. He serves as an advisor to a range of governments and public, private equity and venture capital investors. Dr. Roelofs received his Ph.D. in Organic Chemistry from the University of Nevada, Reno, an M.S. in Organic Chemistry from Iowa State University, and a Bachelor of Science in chemistry, biology and German from Simpson College.

Positions